NCT04001777 2025-10-01A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsAscentage Pharma Group Inc.Phase 1 Active not recruiting80 enrolled
NCT04210037 2022-07-12Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerAscentage Pharma Group Inc.Phase 1/2 Terminated28 enrolled
NCT03387332 2021-08-27APG-1252 in Patients With SCLC or Advanced Solid TumorsAscentage Pharma Group Inc.Phase 1 Terminated24 enrolled